Completed PHASE4 INTERVENTIONAL 2-arm NCT06329258

Combination of Sotyktu and Enstilar for Plaque Psoriasis

A Single Center Study to Evaluate the Effectiveness and Safety of SOTYKTU® (Deucravacitinib) in Combination With Enstilar® for Moderate to Severe Plaque Psoriasis

Sponsor: Psoriasis Treatment Center of Central New Jersey

Conditions Psoriasis

Interventions Deucravacitinib Enstilar

Updated 3 times since 2024 Last updated: Mar 21, 2024 Started: Dec 6, 2022 Primary completion: Nov 13, 2023 Completion: Nov 13, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06329258, this PHASE4 trial focuses on Psoriasis and remains completed. Sponsored by Psoriasis Treatment Center of Central New Jersey, it has been updated 3 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2024 — Jul 2024 [monthly]

Completed PHASE4

First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Psoriasis Treatment Center of Central New Jersey

Data source: Psoriasis Treatment Center of Central New Jersey

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• East Windsor, United States